Skip to main content
Clinical Trials/ACTRN12624000554561
ACTRN12624000554561
Recruiting
N/A

Prospective Study Evaluating The Treatment Outcomes For Localised Recurrent, Resectable Retroperitoneal Liposarcoma in adults.

Australia and New Zealand Sarcoma Association0 sites100 target enrollmentMay 1, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Retroperitoneal Liposarcoma (LPS)
Sponsor
Australia and New Zealand Sarcoma Association
Enrollment
100
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 1, 2024
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Australia and New Zealand Sarcoma Association

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged 18 years or older presenting with first recurrent well\-differentiated and/or dedifferentiated liposarcoma of retroperitoneal space or pelvis after previous macroscopically complete resection (R0/R1 resection)
  • 2\. No distant metastasis on cross\-sectional imaging of chest/abdomen/pelvis (CT and/or MRI) within 1 month to confirm the absence of metastatic disease
  • 3\. Previous histologically proven well\-differentiated or dedifferentiated liposarcoma histology only
  • 4\. Sarcoma not originating from bone or abdominal or gynecological viscera
  • 5\. Tumor confirmed to be resectable with likely R0/R1 resection, and all disease must be deemed to be treatable by RT (joint decision by surgeon and radiation oncologist at a sarcoma multidisciplinary team meeting)
  • 6\. WHO performance status 0\-2
  • 7\. American Society of Anaesthesiologist (ASA) score 1\-3
  • 8\. No prior RT for the retroperitoneal liposarcoma
  • 9\. Prior systemic therapy is allowed
  • 10\. No concurrent active malignancy (except for low risk skin malignancy, low risk prostate carcinoma, low risk breast carcinoma including in situ disease)

Exclusion Criteria

  • 1\. Unresectable disease or likely R2 resection as assessed by the multidisciplinary sarcoma team
  • 2\. Extent of recurrence where preoperative RT to all visible disease is not deemed to be feasible
  • 3\. Contradiction for RT such as history of bowel obstruction or mesenteric ischemia or severe chronic inflammatory bowel disease
  • 4\. Myxoid liposarcoma histology
  • 5\. Pregnancy

Outcomes

Primary Outcomes

Not specified

Similar Trials